Quadrivalent HPV vaccine administered to women who became pregnant during trials did not appear to adversely affect pregnancy outcome; however, use during pregnancy is not recommended

Evidence-Based Medicine

Volumn 15, Issue 3, 2010, Pages 80-81

  Smith McCune, Karen ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; SODIUM CHLORIDE; WART VIRUS VACCINE;

ATTRIBUTABLE RISK; CLINICAL TRIAL; CONCEPTION; CONGENITAL MALFORMATION; DRUG EXPOSURE; FEMALE; FETUS OUTCOME; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; LACTATION; LIVE BIRTH; MATERNAL CARE; NEWBORN CARE; NONHUMAN; NOTE; PREGNANCY; PREGNANT WOMAN; PROSPECTIVE STUDY; TERATOLOGY; TREATMENT OUTCOME;

EID: 77953783793     PISSN: 13565524     EISSN: 14736810     Source Type: Journal    
DOI: 10.1136/ebm1066     Document Type: Note

References (2)

1. Dana A, Buchanan KM, Goss MA, et al. Pregnancy outcomes from the pregnancy registry of a human papillomavirus type 6/11/16/18 vaccine. Obstet Gynecol 2009;114:1170-8.
2. The FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007;356:1915-27.